FDA Logo links to FDA home page
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services home page

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

horizontal rule


FDA Intra-Agency Neurology Working Group


Neurology products regulated by the Food and Drug Administration, comprising drugs, devices, biologics, and combination products, are a diverse group of products aimed at advancing patient care in a number of disease areas for which the unmet therapeutic need is great. Some diseases affect large number of patients, such as Alzheimer’s Disease and Parkinson’s Disease, while other neurological diseases affect smaller numbers of patients, both with devastating consequences for patients and their families.


To improve neurological disease communication across FDA, as a means to:


Dr. Celia Witten, CBER/Director, Office of Cellular, Tissue, and Gene Therapy Dr. Robert Temple, Director, CDER/Office of Drug Evaluation I, Office of Medical Policy


Review staff, supervisory reviewers, senior officials, and project managers, as designated from the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Devices and Radiological Health (CDRH).

Meeting Frequency and Agenda

Meetings scheduled every month by Liza Saavedra, 301-827-5102, liza.saavedra@fda.hhs.gov (or Colleen Locicero, 301-796-1114, colleen.locicero@fda.hhs.gov).

Standing Agenda items to include:

  1. Policy Development (Guidances, Workshops, AC Meetings)
  2. Critical Path Projects
  3. Significant review projects (major investigational/marketing applications under review, marketing approvals, studies of interest, etc.)
  4. Neurology Roundup update
  5. Upcoming Neurology-related meetings
  6. Patient advocate involvement and OSHI updates

Reports will be requested from each group in advance of meetings.

Points of Contact

Status Report

OSHI will draft an annual report for issuance from the group to the Commissioner, and for public release, discussing the work and accomplishments of the group.

horizontal rule